Steroid-induced osteoporosisThirty-nine postmenopausal women aged 55—75 years with at least one osteoporotic fracture were allocated to one year of treatment with the anabolic anabolic steroids osteoporosis nandrolone decanoate 50 mg i. Both groups also ostteoporosis a daily intake of mg calcium. However, this did not reach significance. In the placebo group all bone mineral measurements remained unchanged. The biochemical estimates of bone formation plasma bone Gla protein BGP.
Anabolic Drug Therapy in Osteoporosis | SpringerLink
The use of other anabolic agents such as growth hormone and IGF-I in the treatment of osteoporosis needs further study. Osteoporosis is the result of a disequilibrium between bone formation and bone resorption. Currently, mainly anti-resorptive treatments are available for the treatment of osteoporosis and prevention of fractures estrogens, SERMs, bisphosphonates, calcitonin.
A new approach consists of the use of anabolic treatments, which stimulate bone turnover both bone formation and bone resorption. We will discuss briefly some new insights about fluoride, anabolic steroids, growth hormone, and IGF-I. The use of rhPTH will be reviewed more extensively, as its anti-fracture effect has been well documented. In most cases of osteoporosis, bone resorption is increased; anti-resorptive treatment has been shown to decrease the risk of fracture.
Based on these results, it does not seem logical to use anabolic agents, which increase bone turnover. However, in several clinical situations, bone formation is decreased, such as in the elderly and in glucocorticoid-induced osteoporosis GIOP. In several studies, it has been shown that stimulation of both bone formation and bone resorption with the induction of a positive bone balance can increase bone strength and decrease fracture risk.
Unable to display preview. Anabolic Drug Therapy in Osteoporosis. This process is experimental and the keywords may be updated as the learning algorithm improves. This is a preview of subscription content, log in to check access. J Clin Endocrinol Metab Geusens P, Dequeker J Long-term effect of nandrolone decanoate, I alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodelling and fracture rate in symptomatic osteoporosis: Results of a randomized controlled clinical trial.